CVS Health Corporation (CVS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive sentiment with strong revenue growth in Health Services and Health Care Benefits, despite some declines in operating income. Management's confidence in achieving Medicare Advantage target margins by 2028 and their strategic investments in AI and transparency initiatives further bolster this sentiment. However, conservative guidance and regulatory challenges slightly temper the outlook. Overall, the positive financial performance and strategic initiatives suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Adjusted Operating Income $5.2 billion, an increase of over 12% from the prior year quarter, primarily driven by an improvement in the Health Care Benefits segment.
Adjusted Earnings Per Share (EPS) $2.57, a meaningful increase of over 14% from the prior year quarter, reflecting strong enterprise management.
Revenue Over $100 billion, an increase of over 6% year-over-year, driven by growth across all operating segments.
Cash Flow from Operations Approximately $4.2 billion, reflecting strong operational performance.
Health Care Benefits Revenue Nearly $36 billion, an increase of over 3% from the prior year, primarily driven by the government business, partially offset by the exit from the Individual Exchange business in 2026.
Medical Benefit Ratio (MBR) 84.6%, reflecting a substantial improvement from the prior year quarter due to favorable prior year development and strong medical cost management.
Health Services Revenue Over $48 billion, an increase of 11% year-over-year, driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.
Health Services Adjusted Operating Income Approximately $1.5 billion, a decrease of approximately 7% from the prior year quarter, primarily due to continued pharmacy client price improvements, partially offset by improved purchasing economics and pharmacy drug mix.
Pharmacy & Consumer Wellness Revenue Nearly $32 billion, relatively consistent with the prior year quarter, with increases driven by pharmacy drug mix, increased prescription volumes, and brand inflation, offset by regulatory-related price reductions and generic drug introductions.
Pharmacy & Consumer Wellness Adjusted Operating Income Approximately $1.2 billion, a decrease of approximately 9% from the prior year, impacted by milder seasonal illness and greater weather disruption, but exceeded expectations due to strong underlying business performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Health100 AI Platform: Launching later in 2026, this AI-native platform will integrate payers, PBMs, pharmacies, and providers to create a seamless healthcare experience for consumers.
Biosimilar Adoption: CVS plans to exclude branded STELARA from formularies starting July 2026, replacing it with low-cost biosimilars, aiming for high conversion rates and $0 out-of-pocket costs for most customers.
Medicare Advantage Program: CVS is engaging with CMS to address sustainability issues in the Medicare Advantage program, which remains under pressure from medical cost trends.
Pharmacy Market Share: CVS maintains a retail pharmacy script share of over 29%, showing growth compared to the previous year.
Prior Authorization Process: Aetna has the fewest medical services subject to prior authorization in the industry, with 95% approved within 24 hours and 80% in real time. Efforts are underway to standardize submissions for faster decisions.
Operational Efficiencies: AI has been deployed across CVS to improve operations, enhance consumer experiences, and drive efficiencies.
Focus on Affordability and Transparency: CVS is working to simplify pricing, increase transparency, and lower out-of-pocket costs for patients, including offering insulin for $25 per month.
Technology-Driven Growth: CVS is embedding AI and technology across its operations to drive systemic change and improve consumer engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Advantage Program Sustainability: The Final Rate Notice from CMS is insufficient to offset underlying medical cost trends, which remain above historical levels and have pressured the entire industry, including CVS's Medicare business. This has led to adjusted operating losses in the Medicare segment, requiring further actions to achieve target margins.
Regulatory and Legislative Challenges: Ongoing engagement with CMS, regulators, and legislators is necessary to address detrimental impacts of proposed risk model changes and ensure compliance with evolving regulatory requirements. This includes working with the Federal Trade Commission to reach a settlement, which could impact operations and financials.
Pharmacy Client Price Improvements: Continued pharmacy client price improvements have negatively impacted the Health Services segment's adjusted operating income, despite improved purchasing economics and pharmacy drug mix.
Medical Cost Trends: Medical cost trends remain above historical levels, creating pressure on the company's financial performance and requiring disciplined cost management.
Exit from Individual Exchange Business: The exit from the Individual Exchange business in 2026 has resulted in a sequential decline of approximately 600,000 medical members, impacting revenue and membership growth.
Seasonal Illness and Weather Disruptions: Milder seasonal illness and greater weather disruptions compared to the prior year have negatively impacted the Pharmacy & Consumer Wellness segment's adjusted operating income.
Prior Authorization Process: Efforts to reduce friction in the prior authorization process require collaboration with other stakeholders in the healthcare system to fully adopt standardized services and realize benefits at scale.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Adjusted EPS Guidance: Increased to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20.
Full Year Total Revenues: Expected to be at least $405 billion.
Full Year Cash Flow from Operations: Updated to at least $9.5 billion, reflecting improved underlying performance.
Health Care Benefits Segment Adjusted Operating Income: Expected to be in a range of approximately $4 billion to $4.34 billion, an increase of $420 million relative to prior guidance.
Medical Benefit Ratio (MBR): Full year MBR expected within the previous guidance range of 90.5%, plus or minus 50 basis points.
Pharmacy & Consumer Wellness Segment Adjusted Operating Income: Expected to be at least $6.18 billion, an increase of approximately $90 million from prior guidance.
Enterprise Adjusted Operating Income: Expected to be in the range of $15.53 billion to $15.87 billion for the full year.
Health100 Platform Launch: Planned for later in 2026, designed as an AI-native, state-of-the-art technology and service platform for integrated healthcare experiences.
Biosimilar Adoption Strategy: On July 1, 2026, branded STELARA will be excluded from commercial template formularies, replaced with low-cost biosimilars, aiming for high conversion rates and cost savings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend: Returned nearly $850 million to shareholders through quarterly dividend in the first quarter of 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's thoughts on Medicare Advantage rates for 2027 and their trajectory towards achieving 3% MA margins by 2028?
A:The management emphasized their disciplined strategy and strong execution in Medicare Advantage, resulting in improved geographic and product mix, and leading Star scores. They reaffirmed confidence in achieving target margins by 2028, with meaningful progress expected in 2027.
Q:Can you elaborate on the timing dynamics and competitive changes in the HSS segment, and how these influence the company's guidance?
A:The management noted that HSS modestly exceeded expectations due to strong execution, despite rebate guarantee pressures. They maintained a prudent full-year guidance, emphasizing the importance of creating competition and affordability in the PBM space, and highlighted their transparency initiatives like TrueCost.
Q:What is the approach to HCB guidance and the factors influencing it?
A:The management highlighted strong performance across Aetna, driven by government and commercial businesses. They noted favorable prior year development and strong medical cost management but maintained a conservative approach to guidance due to the early stage of the year.
Q:What is the company's strategy and investment in AI, and when will it shift from net investment to net benefit?
A:The company is heavily investing in AI to improve efficiency, enhance member experience, and reduce costs. They are focusing on AI-driven tools like Informed Choice and Smart Compare. While no specific timeline for net benefit was provided, they emphasized ongoing investments and progress in AI capabilities.
Q:How is the company navigating the current regulatory environment, including PBM legislation and state-level changes like in Tennessee?
A:The company is adapting to federal and state regulatory changes by emphasizing transparency and affordability through initiatives like TrueCost. They expressed disappointment with Tennessee's legislation but are evaluating options, including potential legal action. They remain confident in their ability to adapt and deliver value.
Q:What is the company's perspective on the GLP-1 market and its impact on margins?
A:The company is focused on managing costs in the GLP-1 category through competition and weight management solutions. They have seen a 200 basis point improvement in share growth and emphasized their CostVantage model, which ensures fair margins and affordability for customers.
Q:What is the outlook for the commercial business, including medical cost trends and enrollment?
A:The commercial business is performing well with disciplined pricing and growth across all segments. The company is investing in innovative solutions like navigation and advocacy to enhance member experience and reduce costs. They expressed confidence in the pipeline and outlook for 2027.
Q:What is the company's view on Oak Street's performance and its impact on the year?
A:The company is pleased with Oak Street's performance, emphasizing disciplined growth, adoption of V28, and optimization of their clinical-led model. They remain focused on improving the trajectory of the business and achieving better outcomes.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the specific timeline for when AI investments will shift from net investment to net benefit, using general language about ongoing progress and investments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHIP service
AI CVS
AI ability
AI opportunity
AI state
Aetna friction
America priority
American access
Americans CMS
CMS goal
CMS regulator
Capital Markets
Caremark plan
Commission settlement
Day vision
Executive Vice
Federal Trade
Form report
HUMIRA patient
Markets CVS
President Capital
Vice President
care experience
care system
change health
clinician
company
direction
engagement
example
health care
member provider
month
platform
pocket
priority health
process
provider patient
service authorization
standard
sustainability
CVS Transcript
CVS Health Corporation (CVS) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call presents a positive sentiment with strong revenue growth in Health Services and Health Care Benefits, despite some declines in operating income. Management's confidence in achieving Medicare Advantage target margins by 2028 and their strategic investments in AI and transparency initiatives further bolster this sentiment. However, conservative guidance and regulatory challenges slightly temper the outlook. Overall, the positive financial performance and strategic initiatives suggest a positive stock price movement over the next two weeks.
CVS Health Corporation (CVS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
CVS Health Corporation (CVS) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call shows strong financial performance, with increased EPS guidance, revenue growth, and significant savings from negotiations. The Q&A reveals confidence in overcoming challenges, such as Medicare Advantage rates and FTC regulations, while highlighting strategic investments and market share growth. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase.
CVS Health Corporation (CVS) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call summary presents a positive outlook with increased guidance for EPS and revenue, strong revenue growth across all segments, and improved MBR. The Q&A section reveals confidence in future growth, despite some headwinds. The company's strategic initiatives, such as TrueCost and CostVantage, are progressing well, and management's efforts to address challenges are apparent. However, the goodwill impairment charge and some unclear responses are minor concerns. Overall, the positive aspects outweigh the negatives, suggesting a positive stock price movement in the next two weeks.
CVS Slides
CVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
